Price
$3.67
Increased by 0.00%
Dollar Volume
8.67 M
ADR%
5.39
Earnings Report Date (estimate)
Mar 22, 23 (-0.06)
Market Cap.
810.71 M
Shares Float
192.96 M
Shares Outstanding
220.90 M
Beta
0.89
Price / Earnings
-7.49
BPR
384.97
20D Range
3.26 3.98
50D Range
3.02 3.98
200D Range
1.43 3.98
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 22 -0.08
Increased by +38.46%
-0.08
Aug 10, 22 -0.07
Increased by +50.00%
-0.08
Increased by +12.50%
May 11, 22 -0.13
Increased by +18.75%
-0.08
Decreased by -62.50%
Mar 24, 22 -0.09
Increased by +55.00%
-0.09
Nov 10, 21 -0.13
Increased by +31.58%
-0.14
Increased by +7.14%
Aug 11, 21 -0.14
Increased by +39.13%
-0.15
Increased by +6.67%
May 12, 21 -0.16
Increased by +38.46%
-0.17
Increased by +5.88%
Mar 25, 21 -0.20
Decreased by -11.11%
-0.16
Decreased by -25.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 41.09 M
Increased by +98.69%
-14.90 M
Increased by +15.88%
Decreased by -36.26%
Increased by +57.66%
Jun 30, 22 33.91 M
Increased by +90.15%
-13.76 M
Increased by +27.19%
Decreased by -40.60%
Increased by +61.71%
Mar 31, 22 29.10 M
Increased by +81.34%
-25.01 M
Decreased by -36.06%
Decreased by -85.93%
Increased by +24.97%
Dec 31, 21 -12.13 M
Decreased by -186.90%
-16.65 M
Increased by +14.21%
Increased by +137.28%
Increased by +198.72%
Sep 30, 21 20.68 M
Increased by +101.24%
-17.71 M
Decreased by -4.70%
Decreased by -85.65%
Increased by +47.97%
Jun 30, 21 17.83 M
Increased by +128.96%
-18.91 M
Increased by +6.31%
Decreased by -106.03%
Increased by +59.08%
Mar 31, 21 16.05 M
Increased by +57.34%
-18.38 M
Increased by +4.50%
Decreased by -114.53%
Increased by +39.30%
Dec 31, 20 13.96 M
Increased by +15.94%
-19.41 M
Decreased by -83.77%
Decreased by -139.06%
Decreased by -58.50%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.